House dust mite sublingual immunotherapy for perennial allergic rhinitis～Questionnaire survey of 57 adolescent patients～
2019 Volume 33 Issue 5 Pages 709-717
Details
2019 Volume 33 Issue 5 Pages 709-717
Background : House dust mite sublingual immunotherapy (HDM SLIT) tablet (Actair®) for adolescent allergic rhinitis in Japan has been rarely studied.
Methods : A retrospective observational study of 75 subjects aged 12 to 18 years was conducted using a clinical questionnaire.
From the result of 57 subjects who got the answer of the questionnaire, those who answered ‘very good’ and ‘good’ to the question about symptom improvement were categorized as improvement group, and others were categorized as non-improvement group.
Results : The improvement group was 66.7%. The presence or absence of adverse drug reactions during the first 4 weeks did not affect the efficacy.
In the comparison between the improvement group and the non-improvement group, the significant difference was confirmed in both groups in 2 items of ‘duration of treatment continuation’, and ‘medication adherence’. There were 6 subjects who discontinued the treatment due to worsening of symptoms.
Discussion : It was shown that the efficacy could be expected, if the administration can be habituated, even if the adverse drug reactions appeared after the HDM SLIT tablet initiation. It was important to continue first, and it was proven that the symptom improvement rate rose by continuation of HDM SLIT tablet administration.
